Barclays PLC Has $52,000 Position in Tempus AI, Inc. (NASDAQ:TEM)

Barclays PLC decreased its position in shares of Tempus AI, Inc. (NASDAQ:TEM) by 99.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 926 shares of the company’s stock after selling 137,874 shares during the period. Barclays PLC’s holdings in Tempus AI were worth $52,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in TEM. First Horizon Advisors Inc. bought a new position in shares of Tempus AI in the 3rd quarter valued at $30,000. Vestor Capital LLC bought a new position in Tempus AI in the third quarter valued at about $153,000. Stifel Financial Corp acquired a new stake in shares of Tempus AI during the third quarter valued at about $218,000. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in shares of Tempus AI during the third quarter worth about $258,000. Finally, Clarus Group Inc. acquired a new position in shares of Tempus AI in the third quarter valued at approximately $283,000. 24.22% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Tempus AI news, CEO Eric P. Lefkofsky sold 85,788 shares of the business’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $53.39, for a total transaction of $4,580,221.32. Following the transaction, the chief executive officer now owns 5,771,787 shares in the company, valued at $308,155,707.93. The trade was a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Andrew Polovin sold 51,504 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total value of $2,183,254.56. Following the completion of the sale, the executive vice president now owns 246,085 shares in the company, valued at approximately $10,431,543.15. The trade was a 17.31 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862,758 shares of company stock valued at $79,585,675.

Wall Street Analysts Forecast Growth

TEM has been the topic of several analyst reports. Piper Sandler reiterated a “neutral” rating and issued a $70.00 target price (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Wolfe Research initiated coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and set a $56.00 price target on shares of Tempus AI in a report on Tuesday, January 14th. Finally, Loop Capital dropped their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Tempus AI has an average rating of “Moderate Buy” and an average target price of $56.36.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $51.40 on Friday. The business has a fifty day moving average price of $44.36 and a 200-day moving average price of $47.59. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $79.49.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.